Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD.
Annelies HeylenYannick VermeirenIdo P KemaMartijn van FaassenClaude van der LeyDebby Van DamPeter Paul de DeynPublished in: Pharmaceuticals (Basel, Switzerland) (2023)
These results suggest that the contribution of kynurenine metabolism in neuroinflammation is lower in ALS than in FTD or EOAD and may also be traced back to differences in the age of onset between these disorders. Further research is necessary to confirm the potential of the kynurenine system as a therapeutic target in these early onset neurodegenerative disorders.